SK Biopharmaceuticals (326030) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue reached KRW 512.4B, with cenobamate (XCOPRIⓇ/ONTOZRYⓇ) driving 96% of sales and strong global expansion through licensing and direct US sales.

• Operating profit rose to KRW 157.7B, up from KRW 96.3B in 2024, with net profit at KRW 120.5B, up from a loss in 2023.

• Active R&D in radiopharmaceuticals and targeted protein degradation, with significant investments and partnerships.

Financial highlights

• Revenue increased 40.4% year-over-year to KRW 512.4B, with gross margin at 94.5%.

• Operating profit margin expanded, with operating profit at KRW 157.7B.

• Net profit reached KRW 120.5B, up from a loss of KRW 35.4B in 2023.

• SG&A expenses increased 13.3% year-over-year to KRW 114.1B.

• Basic EPS: KRW 1,665 (2025 Q3), up from negative KRW 420 (2023).

Outlook and guidance

• XCOPRIⓇ sales are on track to reach the upper end of FY guidance ($420M–$450M), with global launches and regulatory filings planned.

• R&D to accelerate in radiopharmaceuticals and TPD, leveraging AI drug design and open innovation.

• Other revenue guidance for FY remains at KRW 65B.

• Pipeline advancements expected, including NDA and IND submissions within the year.